NASDAQ:PHASPhaseBio Pharmaceuticals Stock Price, Forecast & News

PhaseBio Pharmaceuticals' stock was trading at $3.13 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, PHAS shares have increased by 89.1% and is now trading at $5.92. View which stocks have been most impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PhaseBio Pharmaceuticals in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for PhaseBio Pharmaceuticals.

PhaseBio Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for PhaseBio Pharmaceuticals.

PhaseBio Pharmaceuticals Inc (NASDAQ:PHAS) posted its quarterly earnings results on Tuesday, May, 12th. The company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.42) by $0.10. The company earned $0.32 million during the quarter, compared to analyst estimates of $0.38 million. PhaseBio Pharmaceuticals had a negative net margin of 2,310.60% and a negative return on equity of 70.50%. View PhaseBio Pharmaceuticals' earnings history.

6 brokerages have issued 12 month price objectives for PhaseBio Pharmaceuticals' shares. Their forecasts range from $4.00 to $18.00. On average, they anticipate PhaseBio Pharmaceuticals' stock price to reach $13.00 in the next year. This suggests a possible upside of 119.6% from the stock's current price. View analysts' price targets for PhaseBio Pharmaceuticals.

Media stories about PHAS stock have been trending extremely positive this week, InfoTrie reports. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. PhaseBio Pharmaceuticals earned a coverage optimism score of 5.0 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news aboutPhaseBio Pharmaceuticals.

PhaseBio Pharmaceuticals saw a decline in short interest during the month of April. As of April 30th, there was short interest totaling 2,490,000 shares, a decline of 10.1% from the April 15th total of 2,770,000 shares. Based on an average daily trading volume, of 277,500 shares, the short-interest ratio is presently 9.0 days. Currently, 17.9% of the company's stock are short sold. View PhaseBio Pharmaceuticals' Current Options Chain.

Some companies that are related to PhaseBio Pharmaceuticals include Retrophin (RTRX), Kala Pharmaceuticals (KALA), Ardelyx (ARDX), Provention Bio (PRVB), Homology Medicines (FIXX), G1 Therapeutics (GTHX), Vanda Pharmaceuticals (VNDA), Assembly Biosciences (ASMB), Morphic (MORF), ZIOPHARM Oncology (ZIOP), DiaMedica Therapeutics (DMCAF), Stemline Therapeutics (STML), Trillium Therapeutics (TRIL), Radius Health (RDUS) and Syndax Pharmaceuticals (SNDX). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other PhaseBio Pharmaceuticals investors own include Axsome Therapeutics (AXSM), SCYNEXIS (SCYX), Agile Therapeutics (AGRX), Amarin (AMRN), Viking Therapeutics (VKTX), VBI Vaccines (VBIV), TapImmune (MRKR), Selecta Biosciences (SELB), Zynerba Pharmaceuticals (ZYNE) and Dynavax Technologies (DVAX).

(PHAS) raised $66 million in an IPO on Thursday, October 18th 2018. The company issued 5,000,000 shares at $12.50-$14.00 per share. Citigroup, Cowen and Stifel acted as the underwriters for the IPO and Needham was co-manager.

PhaseBio Pharmaceuticals trades on the NASDAQ under the ticker symbol "PHAS."

PhaseBio Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Wellington Management Group LLP (13.99%), BlackRock Inc. (3.44%), Ghost Tree Capital LLC (1.73%), DAFNA Capital Management LLC (1.11%), State Street Corp (0.87%) and Geode Capital Management LLC (0.75%). Company insiders that own PhaseBio Pharmaceuticals stock include Clay Thorp, John P Sharp, Jonathan P Mow, Linda Tufts, Michael York, Nancy J Hutson and Venture Advisors Iii Hatteras. View institutional ownership trends for PhaseBio Pharmaceuticals.

PHAS stock was sold by a variety of institutional investors in the last quarter, including DAFNA Capital Management LLC, Morgan Stanley, BlackRock Inc., UBS Group AG, and First Trust Advisors LP. View insider buying and selling activity for PhaseBio Pharmaceuticals.

PHAS stock was purchased by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Ghost Tree Capital LLC, Geode Capital Management LLC, State Street Corp, Sabby Management LLC, Wells Fargo & Company MN, Bank of New York Mellon Corp, and Nuveen Asset Management LLC. Company insiders that have bought PhaseBio Pharmaceuticals stock in the last two years include Clay Thorp, John P Sharp, Jonathan P Mow, Linda Tufts, Michael York, Nancy J Hutson, and Venture Advisors Iii Hatteras. View insider buying and selling activity for PhaseBio Pharmaceuticals.

Shares of PHAS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of PHAS stock can currently be purchased for approximately $5.92.

PhaseBio Pharmaceuticals has a market capitalization of $170.38 million and generates $2.36 million in revenue each year. The company earns $-39,250,000.00 in net income (profit) each year or ($1.43) on an earnings per share basis. PhaseBio Pharmaceuticals employs 40 workers across the globe.

The official website for PhaseBio Pharmaceuticals is www.phasebio.com.

PhaseBio Pharmaceuticals' mailing address is 1 Great Valley Parkway Suite 30, Malvern PA, 19355. The company can be reached via phone at 610-981-6500 or via email at [email protected]